Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2024-03-06 00:00:00 ET · period of report 2024-03-04 · accession 0001415889-24-007040 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-03-06 | 2024-03-04 | ARQT | Heron Patrick J | Dir | P - Purchase | $9.50 | +21.1K | 8.79M | +0.2% | +$200.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-04 | P | A | 21,052 | $9.50 | 8,785,284 | I By Frazier Life Sciences VIII, L.P. | — | — | (F1) The shares are held directly by Frazier Life Sciences VIII, L.P. FHM Life Sciences VIII, L.P. is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C. is the general partner of FHM Life Sciences VIII, L.P. James N. Topper and the Reporting Person are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences VIII, L.P. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |